Evidence map›Paper›PMID 24435119›Full record

ArticleClinical & experimental metastasis2014

Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.

Kimberley L Kaufman, Swetlana Mactier, Nicola J Armstrong, Duthika Mallawaaratchy, Scott N Byrne, Lauren E Haydu, Valerie Jakrot, John F Thompson, Graham J Mann, Richard A Scolyer and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kimberley L KaufmanSchool of Molecular Bioscience, University of Sydney, Sydney, NSW, 2006, Australia. kim.kaufman@sydney.edu.au.
Swetlana MactierSchool of Molecular Bioscience, University of Sydney, Sydney, NSW, 2006, Australia.
Nicola J ArmstrongGarvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.
Duthika MallawaaratchySchool of Molecular Bioscience, University of Sydney, Sydney, NSW, 2006, Australia.
Scott N ByrneDiscipline of Infectious Diseases and Immunology Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
Lauren E HayduMelanoma Institute Australia, North Sydney, NSW, 2060, Australia.
Valerie JakrotMelanoma Institute Australia, North Sydney, NSW, 2060, Australia.
John F ThompsonMelanoma Institute Australia, North Sydney, NSW, 2060, Australia.
Graham J MannMelanoma Institute Australia, North Sydney, NSW, 2060, Australia.
Richard A ScolyerMelanoma Institute Australia, North Sydney, NSW, 2060, Australia.
Richard I ChristophersonSchool of Molecular Bioscience, University of Sydney, Sydney, NSW, 2006, Australia.
University of Sydney · AUMelanoma Institute Australia · AUMillennium Institute · BRUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need to identify more accurate prognostic biomarkers in melanoma patients, particularly in those with metastatic disease. This study aimed to identify melanoma and leukocyte surface antigens predictive of survival in a prospective series of AJCC stage IIIb/c melanoma patients (n = 29). Live cell suspensions were prepared from melanoma metastases within lymph nodes (LN). The suspensions were immuno-magnetically separated into CD45(+) (leukocyte) and CD45(-) (non-hematopoietic, enriched melanoma cell) fractions. Surface antigens on CD45(-) and CD45(+) cell populations were profiled using DotScan™ microarrays (Medsaic Pty. Ltd.) and showed differential abundance levels for 52 and 78 antigens respectively. Associations of the surface profiles with clinicopathologic and outcome data (median follow-up 35.4 months post LN resection) were sought using univariate (log-rank test) and multivariate (Wald's test; modelled with patient's age, gender and AJCC staging at LN recurrence) survival models. CD9 (p = 0.036), CD39 (p = 0.004) and CD55 (p = 0.005) on CD45(+) leukocytes were independently associated with distant metastasis-free survival using multivariate analysis. Leukocytes with high CD39 levels were also significantly associated with increased overall survival (OS) in multivariate analysis (p = 0.016). LNs containing leukocytes expressing CD11b (p = 0.025), CD49d (p = 0.043) and CD79b (p = 0.044) were associated with reduced OS on univariate analysis. For enriched melanoma cells (CD45(-) cell populations), 11 surface antigens were significantly correlated with the disease-free interval (DFI) between diagnosis of culprit primary melanoma and LN metastasis resection. Nine antigens on CD45(+) leukocytes also correlated with DFI. Following validation in independent datasets, surface markers identified here should enable more accurate determination of prognosis in stage III melanoma patients and provide better risk stratification of patients entering clinical trials.

Indexed as

AdultAgedAged, 80 and overAntigens, SurfaceBlotting, WesternFemaleHumansLeukocytesLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm StagingPrognosisProspective StudiesSkin NeoplasmsAntigens, SurfaceAntibody microarrayCD antigenMetastatic melanomaPrognosisSurvival

Identifiers

PMID24435119
PMCPMC3973954
OpenAlexW1987032807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.